ferric derisomaltose
Selected indexed studies
- Ferric Derisomaltose. (, 2006) [PMID:29999956]
- Intravenous ferric derisomaltose in patients with heart failure and iron deficiency in the UK (IRONMAN): an investigator-initiated, prospective, randomised, open-label, blinded-endpoint trial. (Lancet, 2022) [PMID:36347265]
- An evaluation of ferric derisomaltose as a treatment for anemia. (Expert Rev Hematol, 2021) [PMID:33317356]
_Worker-drafted node — pending editorial review._
Connections
ferric derisomaltose is a side effect of
Sources
- Ferric Derisomaltose. (2006) pubmed
- Intravenous ferric derisomaltose in patients with heart failure and iron deficiency in the UK (IRONMAN): an investigator-initiated, prospective, randomised, open-label, blinded-endpoint trial. (2022) pubmed
- An evaluation of ferric derisomaltose as a treatment for anemia. (2021) pubmed
- Ferric Derisomaltose. (2023) pubmed
- Intravenous ferric derisomaltose for the treatment of iron deficiency anemia. (2021) pubmed
- Hypophosphataemia following ferric derisomaltose and ferric carboxymaltose in patients with iron deficiency anaemia due to inflammatory bowel disease (PHOSPHARE-IBD): a randomised clinical trial. (2023) pubmed
- Intravenous ferric derisomaltose versus oral iron for persistent iron deficient pregnant women: a randomised controlled trial. (2023) pubmed
- A systematic literature review and meta-analysis of the incidence of serious or severe hypersensitivity reactions after administration of ferric derisomaltose or ferric carboxymaltose. (2023) pubmed
- Effects of Iron Isomaltoside vs Ferric Carboxymaltose on Hypophosphatemia in Iron-Deficiency Anemia: Two Randomized Clinical Trials. (2020) pubmed
- PMID:42118883 (2026) pubmed